Phase 0/1 of positron emission tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung cancer (NSCLC). Comparison of the tumor mutation burden ...
Since its discovery by Arnold Levine in 1979, the tumor protein p53 has transformed the field of cancer research. p53 signaling plays a key role in regulating the cell cycle, maintaining genome ...
Researchers at Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH) have used mRNA nanoparticles to reprogram the tumor microenvironment of liver cancer and restore the function ...
Cancer has been recently shown to be affected by protein clusters, particularly by the aggregation of mutant variants of the tumor suppressor protein p53, which are present in more than half of ...
Targeting the Tumour-Specific Spliceosome Through In Silico Virtual Screening for Discovery of New SF3B1 Small Molecule Inhibitors This is an ASCO Meeting Abstract from the 2018 World Cancer Congress ...
Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results